Hims & Hers Health Shares Rise on HHS Compounding Peptides Regulatory Progress

Key Facts

1Hims & Hers Health shares rose as the U.S. Department of Health and Human Services (HHS) moves forward with a plan for compounding peptides.

Hims & Hers Health shares rose as the U.S. Department of Health and Human Services (HHS) moves forward with a plan for compounding peptides. Seeking Alpha reported that the HHS has submitted an interim access policy for compounded pharmacies to make peptides for White House review.

HIMS closed at $27.72 on October 14, 2026, with the stock reaching a day high of $29.68 and a low of $27.57. The advancement of these regulatory plans is expected to provide clarity or potential tailwinds for companies like HIMS that operate in the personalized health and compounding space.